Charles Cherington, who holds about a 10% stake in Ernexa Therapeutics Inc. (NASDAQ: ERNA), bought 4,000,000 shares of the company’s common stock at $0.50 per share on February 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The cash outlay for the equity portion of the purchase totaled $2,000,000.
Alongside the share purchase, the filing shows Cherington received 4,000,000 warrants to acquire common stock at an exercise price of $0.68. Those warrants carry a stated expiration that is the earlier of February 10, 2031, or the 180th day after the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
The $0.50 purchase price per share is materially higher than Ernexa’s trading price at the time of the report, which stood at $0.33, and comes while the company’s market capitalization is reported at $9.18 million. The Form 4 indicates that, after the transaction, Cherington directly holds 6,779,440 shares of common stock and retains the 4,000,000 warrants.
Footnotes in the filing specify that the reported shares and warrants were purchased as part of Ernexa’s follow-on offering. That offering itself was disclosed recently by the company as a $10.5 million public placement, pricing 21 million common shares at $0.50 per share and including warrants to purchase an additional 21 million shares at $0.68 per share. The offered warrants are described as exercisable immediately and set to expire either five years from issuance or 180 days after the public release of clinical trial data, consistent with the terms tied to Cherington’s warrants.
The filing and company disclosures arrive amid a mix of operational and clinical updates for Ernexa. The company said it had been selected to participate in the Japan Entry Acceleration Program (JEAP), a move the company framed as relevant to Japan’s regenerative medicine ecosystem. Ernexa also reported successful regulatory alignment with the U.S. Food and Drug Administration for its ovarian cancer therapy candidate, clearing the path toward an Investigational New Drug application and potential human testing.
In scientific communications, the company presented preclinical data at the American Society of Hematology Annual Meeting that the company described as promising, showing its cell therapy platform’s potential to alter tumor microenvironments. Despite those presentations and regulatory steps, the stock declined after the conference presentation.
Third-party data cited in the filing notes indicate Ernexa is burning through cash and exhibits heavy share-price volatility, with a reported beta of 6.74. The Form 4 and accompanying disclosures identify the recent purchases as part of the company’s capital-raising activity and link warrant expiry mechanics to clinical-data milestones rather than fixed calendar dates alone.
Clear summary
Charles Cherington purchased 4,000,000 shares at $0.50 and 4,000,000 warrants at $0.68 on February 10, 2026, in Ernexa Therapeutics’ follow-on offering, increasing his direct holdings to 6,779,440 shares and 4,000,000 warrants. The transaction occurred while the company reported clinical and regulatory progress and maintained a market cap of $9.18 million.